Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes

• Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics.
• New approach allows doctors, researchers to predict more accurately which treatments may work better.
• Helomics’ database, largest of its kind, is comprised of ovarian, head and neck, colon and pancreas tumors.

Science has discovered that thumbprints and DNA aren’t the only biological elements that make individuals unique. In fact, ears, eyes, tongues and even the way a person walks is distinctive, unlike anybody else in the world (https://ibn.fm/SJX27). Moreover, the things that make people different from each other don’t stop at physical characteristics. Predictive Oncology (NASDAQ: POAI) is building a business around precision medicine, an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that information to provide individualized treatments designed to ultimately improve patient outcomes (https://ibn.fm/Va9HX).

“This new approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people,” explains a MedLinePlus article. “It is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.”

POAI realizes that “just genomics” is not enough to deliver personalized therapeutic options. The company believes that a multi-omic approach to disease, or one that gathers data from multiple levels such as genome, epigenome, transcriptome, proteome and metabolome, offers a much greater chance of success. With that in mind, Predictive Oncology is addressing cancer, specifically ovarian cancer, by leveraging the synergies of two of its wholly owned subsidiaries — Helomics and TumorGenesis — to bring precision medicine to the space.

One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome. The company accomplishes this through its subsidiary Helomics and by using its proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from more than 15 years of clinical testing.

“We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (AI) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process,” the company explains (https://ibn.fm/GRRXb). “We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly.”

Helomics’ database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. The company’s CLIA-certified lab provides testing that assists oncologists in identifying personalized patient treatment options. TumorGenesis is developing a new approach to growing tumors in the laboratory without the use of rats or mice. This exclusive methodology “fools” the tumor into thinking it is still in the body; therefore, it reacts as it naturally would, increasing the accuracy of the biomarker. These biomarkers are then used in TumorGenesis’ Oncology Capture Technology platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples. The process provides critical information that can be used to develop patient-specific treatment options.

For more information on Predictive Oncology, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.